AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03707197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Ten minutes of meditation per day for 8 weeks using a mobile application
Study NCT00956748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprodex
Description: Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
Study NCT00956748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprodex and 2% NAC
Description: Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
Study NCT02954965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reward
Description: Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are rewarding and pleasurable and to integrate these activities into their schedule.
Study NCT02954965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach
Description: Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are challenging, but important to their long-term goals and values, and to integrate these activities into their schedule.
Study NCT01704638 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluvoxamine
Study NCT01704638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvoxamine
Study NCT01704638 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Digoxin
Study NCT03389477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: -Cetuximab must not be administered as an IV push or bolus
Study NCT03389477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: -Patients will receive cisplatin via intravenous (IV) infusion over 60 minutes.
Study NCT03389477 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: -Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays
Study NCT03389477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: * Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy~* If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline.
Study NCT03389477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: Baseline and post-treatment
Study NCT01704638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study NCT03322072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-Time Position Transponder Beacons
Description: The anchored lung tracking beacons are passive electromagnetic transponder beacons which are placed immediately adjacent to a lung tumor using a bronchoscope. Three beacons will be placed in the small airways of the lung adjacent to the target tumor (within 3 cm of the tumor). Each beacon measures 2 mm in diameter and 8 mm in length and consists of a miniature electrical circuit that is encapsulated in a biocompatible glass capsule. Each beacon has an affixed five-legged anchoring system which expands to 5mm diameter once deployed. The Calypso transponder beacon is placed endobronchially using the working channel of a bronchoscope. Navigational bronchoscopy can be used to pre-plan the optimal location for each beacon to be placed within the airways by using a pre-bronchoscopy CT scan.
Study NCT02533570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Study NCT02533570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04574167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
Study NCT04574167 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
Study NCT03316300 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NT-501
Description: Each NT-501 implant consisted of hCNTF-secreting NTC-201-6A.02 cells encapsulated within supportive matrices and surrounded by a semipermeable polymer membrane.~The NTC-201-6A cells continuously secrete CNTF from the NT-501 implant into the vitreous cavity. Implanted by a qualified Health Care Professional.
Study NCT03316300 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: The sham surgery involved a superficial conjunctival incision performed under local anesthetic and closure with a single suture.
Study NCT01791036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Examination of the adductor canal using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin in the medial upper-thigh region. The ultrasound probe will be moved either cephalad or caudad from its initial position in order to visualize the femoral artery immediately deep to the middle of the sartorius muscle. This point will then be selected as the appropriate level for needle insertion. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
Study NCT01791036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Examination of the femoral nerve using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin at the level of the femoral crease. The femoral artery will be identified and the femoral nerve will then be located immediately lateral to the artery, deep to the fascia iliaca and superficial to the iliopsoas muscle. The needle will be positioned next to the femoral nerve. Following this 20 ml of 0.25% bupivacaine with epinephrine will be injected incrementally over a 1 to 2 minute period. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
Study NCT04126798 — intervention group
Intervention type: OTHER
Intervention: Behavioural
Description: Assessment of the 2BALANCE protocol: dual-task protocol consisting of a motor task, cognitive task, and motor-cognitive dual-tasks
Study NCT04495218 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Performed a 10 ml blood sample (2 unnamed samples of 5ml) in each of the 100 patients included.
Study NCT02678182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250 mg/m2/day, 21 day cycle
Study NCT02678182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)
Description: IV treatment on days 1\&15 of 28 day cycle
Study NCT02678182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 6mg/kg on day 1 cycle every 21 days
Study NCT02678182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: 600mg PO twice daily
Study NCT02678182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: ramucirumab 8mg/kg IV day 1 and day 8
Study NCT03600324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T-REV
Description: For any intervention that involves physical exercise, four parameters must be specified to complete the prescription; Type (mode), Intensity, Frequency, and Time. o The standard of care vestibular rehabilitation exercise program consists of three types of treatments that target the specific impairments and limitations discovered during the examination. The three types are: 1) gaze stabilization for vestibulo-ocular reflex dysfunction, 2) visual-vestibular habituation exercise for visual motion sensitivity, and 3) balance exercises for standing balance or gat dysfunction.
Study NCT02206204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Study NCT02700607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Crystalloid
Description: crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study NCT02700607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous HES
Description: HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study NCT01711554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV
Study NCT01711554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO
Study NCT01711554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01711554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01711554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02428062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodynamic target
Description: The anaesthesiologist is requested to maintain intraoperative mean arterial blood pressure of the patient within 10% of the baseline mean arterial blood pressure (recorded during the preoperative evaluation) of that patient. In order to reach this hemodynamic target the anesthesiologist can choose between one or more of the following four sub-interventions:~1. vasoconstrictor agents (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine)~2. intravenous fluids~3. patient's positioning~4. reduction of depth of anesthesia
Study NCT02428062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine 0.1-0.2 mg intravenous bolus
Study NCT02428062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous fluids
Description: A crystalloid fluid bolus is given intravenously (5-10 ml/kg)
Study NCT02428062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient's positioning
Description: The operating table is positioned so that the patient's head lies below the level of the patient's feet (Trendelenburg position) in order to increase venous return
Study NCT02428062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduction of depth of anesthesia
Description: The halogenated anesthetic vapor's inspiratory fraction is decreased in order to reduce the associated peripheral vasodilation
Study NCT02428062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Ephedrine 5-25 mg intravenous bolus
Study NCT02206204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin-matching placebo
Study NCT00708422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
Study NCT00708422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005% (XALATAN®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
Study NCT03196024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-focused intervention arm
Description: Family pairs including an individual family member at-risk for type 2 diabetes or CVD and a co-participating family member will be enrolled in the study. After completing baseline data they will be randomly selected to participate in one of the two study arms. For the family-focused arm, the family pair will attend 8 2-hour weekly educational sessions about type 2 diabetes and CVD risk reducing lifestyle behaviors. The sessions will be presented by community health workers (CHWs) in Spanish to groups of 5 to 6 family pairs. Following completion of the sessions, data will be collected from the family pairs. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the family pairs.
Study NCT03196024 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual-focused intervention arm
Description: Family pairs including an individual family member at-risk for type 2 diabetes or CVD and co-participating family member will be enrolled in the study. After completing baseline data pairs will be randomly selected to participate in one of two interventions. For the individual-focused intervention, the at-risk individual will attend 8 weekly 2-hour education sessions on type 2 diabetes and CVD risk reducing lifestyle behaviors. Sessions will be presented by CHWs in Spanish to groups of 10 to 12 individuals. Following completion of sessions, data will be collected from the individuals. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the at-risk individuals and their co-participating family members.
Study NCT06046027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accupressure band
Description: The accupressure band and wirst band will be place 20 minutes prior to induction of anaesthesia. The induction and maintenance of anaesthesia performed at the discretion of the supervising anaesthesiologist. The maintenance of anaesthesia was achieved by administering sevoflurane at a minimum alveolar concentration (MAC) range of 1 to 1.2. A fresh gas flow rate of 2 L/min comprising a 50:50 concentration mixture of oxygen and air were employed. The patients will be ventilated and maintain end-tidal carbon dioxide (ETCO2) levels within the range of 35-40mmHg. All patients were administered intravenous dexamethasone at a dosage of 0.1mg/kg as a conventional prophylaxis for postoperative nausea and vomiting (PONV) following the induction of anaesthesia. Additionally, intravenous morphine was administered at a dosage of 0.05mg/kg and suppositories containing paracetamol were given at a dosage of 30mg/kg for analgesic purposes. Patients will be extubated at the end of surgery
Study NCT06046027 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Accupressure band
Description: The accupressure band and wirst band will be place 20 minutes prior to induction of anaesthesia. The induction and maintenance of anaesthesia performed at the discretion of the supervising anaesthesiologist. The maintenance of anaesthesia was achieved by administering sevoflurane at a minimum alveolar concentration (MAC) range of 1 to 1.2. A fresh gas flow rate of 2 L/min comprising a 50:50 concentration mixture of oxygen and air were employed. The patients will be ventilated and maintain end-tidal carbon dioxide (ETCO2) levels within the range of 35-40mmHg. All patients were administered intravenous dexamethasone at a dosage of 0.1mg/kg as a conventional prophylaxis for postoperative nausea and vomiting (PONV) following the induction of anaesthesia. Additionally, intravenous morphine was administered at a dosage of 0.05mg/kg and suppositories containing paracetamol were given at a dosage of 30mg/kg for analgesic purposes. Patients will be extubated at the end of surgery
Study NCT04331756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guiding Emergence From Anaesthesia With Tragus Pressure
Description: Use of tragus pressure in guiding patients from emergence from anaesthesia post-surgery
Study NCT04331756 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Guiding Emergence From Anaesthesia Without Tragus Pressure
Description: Usual clinical routine practice in guiding patients from emergence from anaesthesia post-surgery
Study NCT01659567 — intervention group
Intervention type: DRUG
Intervention: Pegylated Interferon Alfa-2a
Description: Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
Study NCT01659567 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
Study NCT05140096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Modify as Participants will receive a single oral dose of 100 mg (1 X 100 mg capsule) acalabrutinib either on Day 1 of Period 1 (Treatment A) and Day 1 of Period 2 (Treatment B) or Day 5 of Period 2 (Treatment C).
Study NCT05140096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Participants will receive 400 mg fluconazole (2 × 200 mg tablets) on Day 1 Period 2 (Treatment B).
Study NCT05140096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Participant will receive oral dose of 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) three times daily on Day 1 and 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) once daily on Days 2 to 5 in Period 2 (Treatment C).
Study NCT03066999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopy
Description: Patients will assign to either Group Cystoscopy (catheter placement via cystoscopy)
Study NCT03066999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DirectVision
Description: Patients will assign to either Group DirectVision (catheter placement via DirectVision)
Study NCT04879810 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sigmoidoscopy and biopsy, blood work
Description: Flexible tube up lower colon, blood draws, quality of life questionnaires
Study NCT04726202 — intervention group
Intervention type: OTHER
Intervention: Standard procedure
Description: Coding of cases follows the standard procedures established at the hospital
Study NCT04726202 — intervention group
Intervention type: OTHER
Intervention: precoding
Description: Standard coding will be reviewed by dedicated physicians and corrected or extended if necessary.~Coding will compared to the written OP report for consistency. Dedicated physician visits patients daily (in addition to routine visits). Dedicated physicians review discharge report and will make changes and additions. DRG coding will be adapted to results from visits and discharge report.
Study NCT01580878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine Hydrochloride Cream, 1%
Description: Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
Study NCT02428062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine 5-10 mcg intravenous bolus
Study NCT02428062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine 0.01 - 0.1 mcg/kg/min intravenous continuous infusion
Study NCT02428062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: Dopamine 5 - 10 mcg/kg/min intravenous continuous infusion
Study NCT03756129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821
Description: Different dosages and different regimen for MIJ821
Study NCT03756129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion
Study NCT03756129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Infusion
Study NCT02369640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Error-management training vs error-avoidance training. Defined by training instructions.
Description: . Error-avoidance training: The participants are instructed to follow the simulator program step-by-step, to achieve the highest possible simulator metric scores by making as few errors as possible, and only to follow the task required in the training program.~Study group 2. Error-management training: The participants are required to complete the same training program as study group 1. The participants are instructed to experiment and explore on their own and to deliberately make errors during the task that they are instructed to perform. Participants are instructed to reflect on their errors based on the simulator metrics that they do not pass. Errors are framed as positive events and instructor comments may include statements such as the more errors you make, the more you learn! or you have made an error? Great! Because now you can learn something new!
Study NCT01905137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intervention-Botulinum Toxin Type A
Description: Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.
Study NCT01905137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00269893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: 0.25 mg/kg of body weight of abciximab either bolus or infusion.
Study NCT00269893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo soulution either bolus or infusion.
Study NCT00269893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo soulution either bolus or infusion.